The AutoCart™ surgical technique is for the treatment of symptomatic articular cartilage defects. This surgical approach is a single-stage, matrix-augmented, autologous chondrocyte transplantation that combines articular cartilage collected using the GraftNet™ device with BioCartilage® extracellular matrix.
The Angel system is the only fully automated system that utilizes 3-sensor technology (3ST) and one-button automation to prepare customized platelet-rich plasma (PRP) formulations. The Angel system has the capability to deliver platelet concentrations up to 18x baseline with adjustable leukocyte concentrations. The Angel system utilizes the principle of flow cytometry, or light absorption by cells, to achieve precise separation with reproducible results. Platelet-rich plasma may be mixed with allograft and autograft bone prior to application to an orthopedic site.
Angel System Calculator Web Application
The Arthrex ACP double-syringe system is used to facilitate the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient’s point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements. There has been increased interest in autologous blood products for use in a number of orthopedic therapies.
Products in this comprehensive line of AlloSync bone grafting solutions are derived from human allograft bone and maintain optimal osteoinductive and osteoconductive potential. The comprehensive portfolio includes a wide selection of advanced demineralized bone matrix (DBM) graft options: - AlloSync Pure demineralized bone matrix - AlloSync Expand demineralized cortical fibers - AlloSync demineralized cancellous sponges and cortical fibers - AlloSync putty, gel, and paste AlloSync products provide excellent handling characteristics and can be combined with bioactive fluids such as platelet-rich plasma (PRP) or bone marrow aspirate (BMA).
ArthroFlex dermal allograft is an acellular dermal extracellular matrix intended for supplemental support and covering for soft-tissue repair. MatrACELL®* technology, a patented and validated process, renders the ArthroFlex allograft dermis acellular without compromising biomechanical or biochemical properties. This process allows the matrix to retain its growth factors, native collagen scaffold, and elastin, which are required for healing.1 Arthroflex dermal allograft improves the strength of the repair and protects it to allow healing.2,3 MatrACELL technology removes donor DNA from the dermal matrix, ensuring a biocompatible scaffold to facilitate repair. References: 1. Moore MA, Samsell B, Wallis G. Cell Tissue Bank. 2015;16(2):249-259. doi:10.1007/s10561-014-9467-4. 2. Gilot GJ, Alvarez-Pinzon AM, Barcksdale L, Westerdahl D, Krill M, Peck E. Arthroscopy. 2015;31(8):1459-65. doi:10.1016/j.arthro.2015.02.032 3. Ely EE, Figueroa NM, Gilot GJ. Orthopedics. 2014;37(9):608-614. doi:10.3928/01477447-20140825-05 *ArthroFlex and MatrACELL are registered trademarks of LifeNet Health.
Interfyl connective tissue matrix is used to fill irregular spaces or soft-tissue deficits resulting from wounds, trauma, or surgery. Interfyl connective tissue matrix is suited for a variety of surgical applications when there is a need to replace or supplement damaged or inadequate integumental tissue. *Interfyl® is a product of Celularity Inc.